Cart0Item(s)

You have no items in your shopping cart.

Product was successfully added to your shopping cart.
  • Triazavirin 250mg 20 PCs capsules - Pharmaceutics Triazavirin 250mg 20 PCs capsules - Pharmaceutics
  • Triazavirin 250mg 20 PCs capsules - Pharmaceutics Triazavirin 250mg 20 PCs capsules - Pharmaceutics

Triazavirin 250mg 20 PCs capsules

Quick Overview

Triazavirin is a guanosine nucleotide analog that inhibits RNA synthesis

In Stock
$47.00

Pay attention

Genuine branded medication

Private and confidential

No hidden fees

Free GLOBAL shipping for order over 50 USD

Details

Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain.1,2,4 It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications.5 Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.2

Triazavirin®

Triazavirin is used for treatment of Coronavirus in China in 2020.

Active substance : Methylthionitrooxodihydrotriazolotriazinid
  • Triazavirin has direct antiviral effect (it is not an immunomodulator and not a symptomatic agent)
  • Triazavirin actively combats the influenza virus including avian flu and swine flu, as well as SARS of any etiology
  • Triazavirin is effective at any stage of the disease, and not only in the first hours of the disease

Indications

Treatment of influenza in adults. If necessary, combined with the reception of symptomatic agents.

Name in Cyrillic : Триазавирин

Indication  Triazavirin was developed in Russia as a potential treatment of Influenza A and B infections.3

Pharmacodynamics  Not Available

Mechanism of action Triazavirin is a guanosine nucleotide analog that inhibits RNA synthesis.4,6

Absorption In rabbits, intragastric triazavirin reaches a Cmax of 1.1±0.1mg/L, with a Tmax of 0.40±0.16h, and an AUC of 3.10±0.8mg*h/L.3 In rabbits, intravenous triazavirin has an AUC of 1.2±0.3mg*h/L.3

In humans, triazavirin reaches a Cmax of 4.8µg/mL, with a Tmax of 1-1.5h, and an AUC of 12.8µgµg/h*mL.6

Volume of distribution In rabbits, intragastric triazavirin has a volume of distribution of 83.5±19.2L/kg while intravenous triazavirin has a volume of distribution of 1.2±0.3L/kg.3

Protein binding Data regarding the protein binding of triazavirin is not readily available.

Metabolism Data regarding the metabolism of triazavirin is not readily available.

Route of elimination Data regarding the route of elimination of triazavirin is not readily available.

Half life In rabbits, intragastric triazavirin has a half life of 1.1±0.1h while intravenous triazavirin has a half life of 0.50±0.09h.3

The half life of triazavirin is 1-1.5h.6

Clearance In rabbits, intragastric triazavirin has a clearance of 37.0±11.2L/h*kg while intravenous triazavirin has a clearance of 14.0±3.7L/h*kg.3

The clearance of triazavirin is 246mL/min.6

Toxicity  The intraperitoneal LD50 of triazavirin in mice is 1400±120mg/kg in mice and the intragastric LD50 is 2200±96mg/kg.3

Patients experiencing an overdose may present with nausea, vomiting, dyspepsia, and stomach pain.6 Treat overdose with symptomatic and supportive treatment, which may include discontinuation of treatment.6

Affected organisms 

  • Influenza A virus
  • Influenza B virus

Pathways  Not Available
Pharmacogenomic Effects/ADRs  Not Available

In detail https://www.drugbank.ca/drugs/DB15622

Additional Information

SKU Triazavirin250
Pcs per package 20 pcs
Weight kg. 0.05

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.

  1. Be the first to review this product

Write Your Own Review

How do you rate this product? *

 1 star2 stars3 stars4 stars5 stars
Price
Product description
Quality of goods